Journals / Eurasian Journal of Medicine / 2016 / Cilt: 48 - Sayı: 3

Şaşılık Cerrahisi Sonrası Loteprednol Etabonat %0,5/Tobramisin %0,3 ve Deksametazon %0,1/Tobramisin %0,3 Etkinlik ve Güvenliğinin Karşılaştırılması

Comparison of the Safety and Efficacy of Loteprednol Etabonate 0.5%/Tobramycin 0.3% with Dexamethasone 0.1%/Tobramycin 0.3% Following Strabismus Surgery

Pages
186–188
Publication Date
2022-10-18
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

LE/T, as a new-generation steroid combination product, could be used as a safe and effective anti-inflammatory agent for the treatment of inflammation following strabismus surgery

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Objective: To compare the anti-inflammatory efficacy and safety of 0.5% loteprednol etabonate/0.3% tobramycin (LE/T) and 0.1% dexamethasone/0.3% tobramycin (DM/T) ophthalmic suspensions following strabismus surgery.
📊
Key Findings & Data:Materials and Methods: The records of 40 patients who were treated with either LE/T or DM/T following strabismus surgery were retrospectively reviewed.
💡
Conclusion & Impact:LE/T, as a new-generation steroid combination product, could be used as a safe and effective anti-inflammatory agent for the treatment of inflammation following strabismus surgery
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Objective: To compare the anti-inflammatory efficacy and safety of 0.5% loteprednol etabonate/0.3% tobramycin (LE/T) and 0.1% dexamethasone/0.3% tobramycin (DM/T) ophthalmic suspensions following strabismus surgery. Materials and Methods: The records of 40 patients who were treated with either LE/T or DM/T following strabismus surgery were retrospectively reviewed. The recorded signs and symptoms of inflammation and intraocular pressure of the patients at 1 day, 1 week, and 3 weeks after the surgery were evaluated and compared between the groups. Results: In both groups, reduced inflammation was noted during the follow-up visits. There was no statistically significant difference between the LE/T and DM/T groups with regard to the postoperative scores or measurements, including discomfort, chemosis, secretion, conjunctival hyperemia, and conjunctival gap size (p>0.05), during the follow-up visits. Allergic reactions to the medications were not reported in any patient. Intraocular pressures were within normal limits in both groups. Conclusion: LE/T was found to be as effective as DM/T in reducing inflammation after strabismus surgery. LE/T, as a new-generation steroid combination product, could be used as a safe and effective anti-inflammatory agent for the treatment of inflammation following strabismus surgery

Özet

Amaç: Şaşılık cerrahisi sonrası loteprednol etabonat %0,5/tobramisin %0,3 (LE/T) ve deksametazon %0,1/tobramisin %0,3 (DM/T) oftalmik solüsyonlarının antiinflamatuar etkinlik ve güvenliğinin karşılaştırılması. Gereç ve Yöntem: Şaşılık cerrahisi sonrası, LE/T veya DM/T ile tedavi uygulanmış 40 hastanın kayıtları retrospektif olarak gözden geçirildi. Hastaların cerrahi sonrası 1. gün, 1. ve 3. haftalarda kaydedilen göz içi basınçları, enflamasyona ait semptom ve bulguları değerlendirildi ve gruplar arasında karşılaştırma yapıldı.Bulgular: Her iki grupta, takiplerde enflamasyonun azaldığı değerlendirildi. Operasyon sonrası, LE/T ve DM/T grupları arasında, rahatsızlık hissi, kemozis, sekresyon, konjonktival hiperemi skorları ve konjonktiva açıklık değerleri açısından istatistiki olarak anlamlı bir fark tespit edilmedi. (p>0.05) Hastaların hiçbirisinde alerjik reaksiyon rapor edilmemişti. Göz içi basınçları her iki grupta da normal sınırlar içerisindeydi.Sonuç: LE/T'nin, DM/T kadar şaşılık cerrahisi sonrası inflamasyonun azaltmasında etkin olduğu; yeni jenerasyon steroid kombinasyon ürünü olarak, güvenli ve etkili olarak kullanılabileceği kanaatine varıldı.

🔖

Cite This Article

AKYOL, İ. S. (2022). Şaşılık Cerrahisi Sonrası Loteprednol Etabonat %0,5/Tobramisin %0,3 ve Deksametazon %0,1/Tobramisin %0,3 Etkinlik ve Güvenliğinin Karşılaştırılması. Eurasian Journal of Medicine, Cilt: 48 - Sayı: 3, 186–188. https://ajindex.com/articles/509078

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (2)

  1. Dadeya S, and Kamlesh. Comparative evaluation of diclofenac and dexamethasone following strabismus sur-gery. J Pediatr Ophthalmol Strabismus 2002; 39: 166-8
  2. Snir M, Siegel RA, Friling R, and Weinberger D. Efficacy of diclofenac versus dexamethasone for treatment after strabismus surgery. Ophthalmology 2000; 107: 1884-8. [CrossRef ] 3. Khan HA, Amitava AK. Topical diclofenac versus dexamethasone after strabismus surgery: A dou-ble-blind randomized clinical trial of anti-infalmma-tory effect and ocular hypertensive response. Indian J Ophthalmol 2007; 55: 271-5. [CrossRef ] 4. Amon M, Busin M. Loteprednol etabonate ophthal-mic suspension 0.5%: efficacy and safety for post-operative anti-inflammatory use. Int Ophthalmol 2012; 32: 507-17. [CrossRef ] 5. Pflugfelder SC, Maskin SL, Anderson B, et al. A randomized, double-masked, placebo-controlled, multicenter comparison of loteprednol etabonate ophthalmic suspension, 0.5%, and placebo for treat-ment of keratoconjunctivitis sicca in patients with delayed tear clearance. Am J Ophthalmol 2004;138: 444-57. [CrossRef ] 6. Lane SS, Holland EJ. Loteprednol etabonate 0.5% versus prednisolone acetate 1.0% for the treatment of inflammation after cataract surgery. J Cataract Refract Surg 2013; 39: 168-73. [CrossRef ] 7. White EM, Macy JI, Bateman KM, Comstock TL. Comparison of the safety and efficacy of lotepre-dnol 0.5%/tobramycin 0.3% with dexamethasone 0.1%/tobramycin 0.3% in the treatment of blepha-rokeratoconjunctivitis. Curr Med Res Opin 2008; 24: 287-96. [CrossRef ] 8. Comstock TL, Holland EJ. Loteprednol and tobra-mycin in combination: a review of their impact on current treatment regimens. Expert Opin Pharmacother 2010; 11: 843-52. [CrossRef ] 9. Bartlett JD, Holland EJ, Usner DW, Paterno MR, Comstock TL. Tolerability of loteprednol/tobramy-cin versus dexamethasone/tobramycin in healthy volunteers: results of a 4-week, randomized, dou-ble-masked, parallel-group study. Curr Med Res Opin 2008; 24: 2219-27. [CrossRef ] 10. Holland EJ, Bartlett JD, Paterno MR, Usner DW, Comstock TL. Effects of loteprednol/tobramycin versus dexamethasone/tobramycin on intraocular pressure in healthy volunteers. Cornea 2008; 27: 50-5. [CrossRef ] 11. Comstock TL, DeCory HH. Loteprednol Etabonate 0.5%/Tobramycin 0.3% Compared with Dexamethasone 0.1%/Tobramycin 0.3% for the Treatment of Blepharitis. Ocul Immunol Inflamm 2016; 20: 1-8. [CrossRef ] 12. Comstock TL, Paterno MR, Bateman KM, Decory HH, Gearinger M. Safety and tolerabili